Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Smells like shorts are getting desperate.
By the way, "LOL" means laugh(ing) out loud. You keep posting "LOLOL". That doesn't make any sense, unless you talk like this, "laughing out loud out loud". That's how Jimmy Two Times from the movie Goodfellas talked so maybe you talk like that. Do you talk like that?
The rest of your post is nothing but more of your pure speculation, and what I consider to be blatantly false and misleading claims.
In the 10-K OWCP gave the worst case scenario about how the SEC case against Jeffrey Friedland MIGHT affect the company and stock price. In that 10-K, OWCP is being very honest and frank about the worst case scenario. This is what companies do in their 10-K... they include all the possibilities when it comes to risk.
So what is the worst case scenario?
THIS:
"As a result, we do not know how the SEC investigation is proceeding, when the investigation will be concluded, or if we will become involved to a greater extent than merely responding to the subpoena we received. This may become a material cost to us, distract the time and attention of our officers and directors or divert our resources away from ongoing research and development programs and result in loss of investor confidence and a decline in price of our Common Stock."
THAT'S IT... THERE'S NOTHING ELSE THERE.
And just because this is the worst case scenario doesn't mean that this worst case scenario will happen. OWCP clearly stated in the 10-K they do not know how the SEC investigation against Jeffrey Friedland is proceeding or when the investigation will be concluded.
It might be not take long and responding to the subpoena may end up being the full extent of OWCP's involvement. I can speculate and say that I think it will amount to just that, OWCP will cooperate fully and respond to the non-public subpoena, and that will be the extent of it and the company will move forward, and that is what I actually think will happen.
To state that you know otherwise is pure speculation.
None of your pure speculation and false claims that you keep conjuring up is based in reality.
I-GLOW writes:
"In the SEC complaint against Friedland the SEC made it clear that OWCP was complicit in the fraud by supplying Friedland with a Fraudulent 144 Opinion Letter."
That is false, as in untrue. If you were under oath and testified that, you would be guilty of perjury.
Here's reality:
OWCP has clearly stated that they are not party to this SEC case which is against Jeffrey Friedland, and OWCP has also said very clearly that they had no knowledge of Friedland's fraudulent activity which started in January 2017. Almost all the money JF gained from selling the Global and Intivia shares has been frozen by the SEC in bank accounts/assets. The SEC has made no such action against OWC, and there is not a shred of evidence that a dime went to Israel. The Friedlands had it in Colorado.
The SEC stated very clearly that it was Jefrey Friedland himself who provided the transfer agent with the fraudulent 144 Opinion Letter in January 2017. The opinion letters from 2014 and 2016 were provided by OWC and were not fraudulent.
OWCP is not a defendant in the case, they received a non-public subpoena because they are cooperating with the SEC. Companies get those all the time, very common. They have been totally honest with us investors, and these things happen not just on the OTC, but also with companies on the big boards. This JF issue was an external scheme that Friedland and his wife were the perpetrators of and the Friedlands are the defendants, not OWC. OWCP and it's stock holders (which includes all of the management) were the victims.
OWCP just announced with an 8-K that an institutional investor just invested $5,000,000 in OWCP (as in 5 million dollars). That's FACT.
The stock price has surged since the latest announcement and will continue to do so.
Lots of short squeeze coming, and there's simply nothing you can do about it... not a damn thing!!!
LOL...
Go OWCP !!
clock's ticking
OWCP in the $5 Million Fund Club, with 31 patents in 9 patent families, and a stellar R&D team.
Going to be huge.
Go OWCP !!
BANG! If people are lying, post the FACTS
LOL... shorts be trippin' ..too funny
Yep! OWCP has 31 register patents in 9 patent families and they continue to move forward in the patent process with our patents.
Some people don't understand that the patent process is a process.
The patent work is progressing ahead and our IP will be protected. OWCP has 31 registered patents in 9 patent families. Epic R&D team, $5 MILLION funding from an Institutional Investor... This is huge!
Awesome find Potvinsux !!!
HOD .288 come Monday this will rise even more.
Go OWCP !!
GOLDMAN SACHS has had 339 Regulatory, Civil, & Arbitration Events with 339 EVENTS' Total Disclosures listed with FINRA.
NEWBRIDGE SECURITIES CORPORATION has had 34 Regulatory, & Arbitration Events; and ZERO Civil Events.
Are you inferring that Goldman Sachs is not a reputable broker? I know quite a few brokers and licensed traders that would disagree with you. Heck man I'll go as far as to speculate that Mark Cuban would disagree with you. LOL... How about CHARLES SCHWAB, MERRILL LYNCH, MORGAN STANLEY, EDWARD JONES, etc. etc. etc.
FINRA broker check links for CITICORP SECURITIES SERVICES, INC.,NEWBRIDGE SECURITIES INC. with 2 aforementioned EVENTS
https://brokercheck.finra.org/firm/summary/15387
https://files.brokercheck.finra.org/firm/firm_15387.pdf
FINRA broker check links for NEWBRIDGE SECURITIES with 34 aforementioned EVENTS
https://brokercheck.finra.org/firm/summary/104065
https://files.brokercheck.finra.org/firm/firm_104065.pdf
FINRA broker check links for GOLDMAN SACHS with 339 aforementioned EVENTS
https://brokercheck.finra.org/firm/summary/361
https://files.brokercheck.finra.org/firm/firm_361.pdf
FINRA broker check links for CHARLES SCHWAB with 314 aforementioned EVENTS
https://brokercheck.finra.org/firm/summary/5393
https://files.brokercheck.finra.org/firm/firm_5393.pdf
FINRA broker check links for MERRILL LYNCH with 1557 aforementioned EVENTS
https://brokercheck.finra.org/firm/summary/7691
https://files.brokercheck.finra.org/firm/firm_7691.pdf
FINRA broker check links for MORGAN STANLEY with 443 aforementioned EVENTS
https://brokercheck.finra.org/firm/summary/8209
https://files.brokercheck.finra.org/firm/firm_8209.pdf
FINRA broker check links for EDWARD JONES with 314 aforementioned EVENTS
https://brokercheck.finra.org/firm/summary/250
https://files.brokercheck.finra.org/firm/firm_250.pdf
...I can go all day.
You trying to discredit the $5 MILLION DOLLAR investment in OWCP preferred stock by an Institutional Investor by bringing up past "events" of the broker handling the transaction makes you look like amateur hour. All brokers have such events. What matters is if they are in good standing with FINRA and the SEC; and NEWBRIDGE SECURITIES CORPORATION is in good standing with all regulators including the SEC and FINRA.
You sure are grasping at straws. Shorts better cover soon, but I actually hope the pps drops a bit on Friday so I can load up more for less.
Clock's ticking....
$OWCP
NEWBRIDGE SECURITIES CORPORATION is in good standing with all regulators including the SEC and FINRA.
NEWBRIDGE SECURITIES CORPORATION
CRD# 104065
SEC# 8-52538
Is this brokerage firm currently suspended with any regulator?
No
look it up:
https://brokercheck.finra.org/firm/summary/104065
https://files.brokercheck.finra.org/firm/firm_104065.pdf
OWC Pharmaceutical Research Corp Raises $5 Million in Preferred Stock Sale to Institutional Investor
RAMAT GAN, Israel, May 3, 2018 /PRNewswire/
OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the closing of the sale of $5 million of convertible preferred stock to an institutional investor. The preferred stock is convertible into OWCP common stock at a price of $0.20 per share. Newbridge Securities Corporation, through LifeTech Capital, acted as exclusive placement agent for the transaction.
The company also issued warrants to purchase 12.5 million shares of common stock to the investor.
The preferred stock, designated as Series A Preferred Stock, accrues dividends, payable quarterly, at a rate of 5% per annum on the amount invested, payable, in the company's discretion subject to customary restrictions, in cash or common stock. The preferred stock has a liquidation preference of 120% of the amount invested. The company has certain obligations to redeem preferred stock upon the occurrence of certain events, and as to half of the shares over time, and the right to force a conversion of the preferred stock under certain conditions.
"This financing is an important milestone for the company," said Mordechai Bignitz, CEO of OWC Pharmaceutical Research. "It enables us to continue to invest in the research and development of our products and to progress our clinical development, which is key to the uniqueness of our company. With this financing, we can also consolidate our movement to commercialization of our first products. We are also very happy to strengthen the institutional presence amongst our shareholders."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
Mordechai Bignitz, Chief Executive Officer - OWC Pharmaceutical research crop,
Email: Mordechai.Bignitz@owcpharma.com
Tel: +972-(72)-260-8004
SOURCE OWC Pharmaceutical Research Corp.
First of all, "LOL" means laugh(ing) out loud. You keep posting "LOLOL". That doesn't make any sense, unless you talk like this, "laughing out loud out loud". That's how Jimmy Two Times from the movie Goodfellas talked so maybe you talk like that. Do you talk like that?
The rest of your post is nothing but more of your pure speculation.
In the 10-K OWCP gave the worst case scenario about how the SEC case against Jeffrey Friedland MIGHT affect the company and stock price. OWCP is being very honest and frank about the worst case scenario. This is what companies do in their 10-K... they include all the possibilities when it comes to risk.
So what is the worst case scenario?
THIS:
"As a result, we do not know how the SEC investigation is proceeding, when the investigation will be concluded, or if we will become involved to a greater extent than merely responding to the subpoena we received. This may become a material cost to us, distract the time and attention of our officers and directors or divert our resources away from ongoing research and development programs and result in loss of investor confidence and a decline in price of our Common Stock."
THAT'S IT... THERE'S NOTHING ELSE THERE.
And just because this is the worst case scenario doesn't mean that this worst case scenario will happen. OWCP clearly stated in the 10-K they do not know how the SEC investigation against Jeffrey Friedland is proceeding or when the investigation will be concluded.
It might be not take long and responding to the subpoena may end up being the full extent of OWCP's involvement. I can speculate and say that I think it will amount to just that, OWCP will cooperate fully and respond to the non-public subpoena, and that will be the extent of it and the company will move forward, and that is what I actually think will happen.
To state that you know otherwise is pure speculation.
None of your pure speculation that you keep conjuring up is based in reality.
Here's reality:
OWCP has clearly stated that they are not party to this SEC case which is against Jeffrey Friedland, and OWCP has also said very clearly that they had no knowledge of Friedland's fraudulent activity which started in January 2017. Almost all the money JF gained from selling the Global and Intivia shares has been frozen by the SEC in bank accounts/assets. The SEC has made no such action against OWC, and there is not a shred of evidence that a dime went to Israel. The Friedlands had it in Colorado.
The SEC stated very clearly that it was Jefrey Friedland himself who provided the transfer agent with the fraudulent 144 Opinion Letter in January 2017. The opinion letters from 2014 and 2016 were provided by OWC and were not fraudulent.
OWCP is not a defendant in the case, they received a non-public subpoena because they are cooperating with the SEC. Companies get those all the time, very common. They have been totally honest with us investors, and these things happen not just on the OTC, but also with companies on the big boards. This JF issue was an external scheme that Friedland and his wife were the perpetrators of and the Friedlands are the defendants, not OWC. OWCP and it's stock holders (which includes all of the management) were the victims.
OWCP just announced with an 8-K that an institutional investor just invested $5,000,000 in OWCP (as in 5 million dollars). That's FACT.
Go OWCP !!
$$$$$ GOING TO BE HUGE $$$$$
...tick tock
So now you're pure speculation is that "Bignitz knows the SEC is going to either sanction or prosecute him and the other insiders - why not do a Hail Mary and do a last minute money grab".
LOL... that's ludicrous.
Institutional investors know all about the SEC case against Jeffrey Friedland, and no institutional investor is so stupid that they would invest $5 million in a company that is about to be either sanctioned or prosecuted by the SEC.
What I will speculate is that the institutional investor knows that Jeffrey Friedland was a snake in the grass selling shares for shorts to cover and is now no longer a problem for this stock.
For sure the institutional investor has thoroughly researched ALL the fundamentals of OWCP and see a well positioned strong company with solid fundamentals, and amazing R&D team, 31 registered patents, and at least one product ready to go to market.
OWCP is way undervalued and the PPS is now going to rise out of the Friedland funk and shorts will face a squeeze, and there's nothing you can do about it, not a damn thing. :)
Go OWCP !! $$$$$ GOING TO BE HUGE $$$$$
tick tock
How much cryptocurrency mining has SANP done ?
More pure speculation.
More of your pure speculation.
In the 10-K they are giving the worst case scenario about how the SEC case against Jeffrey Friedland MIGHT affect the company and stock price. OWCP is being very honest and frank about the worst case scenario. This is what companies do in their 10-K... they include all the possibilities when it comes to risk.
So what is the worst case scenario?
THIS:
"As a result, we do not know how the SEC investigation is proceeding, when the investigation will be concluded, or if we will become involved to a greater extent than merely responding to the subpoena we received. This may become a material cost to us, distract the time and attention of our officers and directors or divert our resources away from ongoing research and development programs and result in loss of investor confidence and a decline in price of our Common Stock."
THAT'S IT... THERE'S NOTHING ELSE THERE.
And just because this is the worst case scenario doesn't mean that this worst case scenario will happen. OWCP clearly stated in the 10-K they do not know how the SEC investigation against Jeffrey Friedland is proceeding or when the investigation will be concluded.
It might be not take long and responding to the subpoena may end up being the full extent of OWCP's involvement. I can speculate and say that I think it will amount to just that, OWCP will cooperate fully and respond to the non-public subpoena, and that will be the extent of it and the company will move forward, and that is what I actually think will happen.
To state that you know otherwise is pure speculation.
None of that pure speculation that you keep conjuring up is based in reality.
OWCP has clearly stated that they are not party to this SEC case which is against Jeffrey Friedland, and OWCP has also said very clearly that they had no knowledge of Friedland's fraudulent activity which started in January 2017. Almost all the money JF gained from selling the Global and Intivia shares has been frozen by the SEC in bank accounts/assets. The SEC has made no such action against OWC, and there is not a shred of evidence that a dime went to Israel. The Friedlands had it in Colorado.
OWCP is not a defendant in the case, they received a non-public subpoena because they are cooperating with the SEC. Companies get those all the time, very common. They have been totally honest with us investors, and these things happen not just on the OTC, but also with companies on the big boards. This JF issue was an external scheme that Friedland and his wife were the perpetrators of and the Friedlands are the defendants, not OWC. OWCP and it's stock holders (which includes all of the management) were the victims.
This will pass and in the meantime OWCP will continue their R&D and patent work.
$OWCP
yep.
tick tock ..tick tock
$OWCP
Here is my Question: Should I buy, or not?
OWCP Patent links (7 patent families, 31 patents, and counting) All are active, zero patents rejected. These patents are being amended to perfection. People that actually know about the patent process know that it's a process.
Here are their latest revisions in February 2018.
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
United States Patent and Trademark Office (USPTO) (search from the Patent Application Information Retrieval (PAIR) (patent application # 15536738 and 15629230, and 15708187))
https://www.uspto.gov/patents-application-process/search-patents
World Intellectual Property Organization (simple search One World Cannabis)
https://patentscope.wipo.int/search/en/result.jsf
European Patent Register
https://register.epo.org/smartSearch?searchMode=smart&query=one+world+cannabis
IP Australia
http://pericles.ipaustralia.gov.au/ols/auspat/quickSearch.do?queryString=one+world+cannabis&resultsPerPage=
Canadian Intellectual Property Office
http://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=one+world+cannabis&start=1&num=50&type=basic_search&newSearch=0
Israel Patent Office (click English in top left, then advance search for applicant One World Cannabis)
http://www.ilpatsearch.justice.gov.il/UI/RequestsList.aspx
Dr. Yehuda Baruch stated, “We greatly look forward to introducing this breakthrough tablet to the marketplace”
Dr. Rozenblat stated, "as a scientist I am extremely excited to be part of OWC's study that appears to be a highly possible breakthrough".
And then, on February 18, 2018, OWC Pharmaceutical Research Corp., OTCQB: OWCP, appointed Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO).
Dr Zeevi is an expert in this kind of R&D and getting patents granted and it's very likely that she read every patent application as well as reviewed all of the work OWCP had done before joining the OWCP team. There's no way she would have joined OWCP if it was not legit.
Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem
Dr. Yehuda Baruch who, will now assume the role of Chief Medical and Regulatory Officer of the OWC Pharmaceutical Research Corp. commented:
"I am very pleased that we have reached a stage in our development where we were able to recruit a scientist of the caliber and background of Dr. Yacoby Zeevi. Her past scientific experience and achievements will greatly benefit our endeavors."
Dr. Yacoby Zeevi commented, "I am very proud to join OWCP and cooperate with their excellent management team in order to advance the Company to the next level. The Company has achieved a great deal in its clinical development to date and I am sure I can help in accelerating its growth."
Mr. Mordechai Bignitz, Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Zeevi agree to join OWCP and assume the role of CSO. She brings with her immense pharmaceutical discovery and development knowledge, a unique set of skills and an exceptional track record, which contributed significantly to the success of her previous company. Her addition will complement our management team extremely well."
Read it all, do your own DD.
$OWCP Long and Strong.... $$$$$ GOING TO BE HUGE! $$$$$
I'm glad OWCP is working on the R&D and patents instead of just putting out news to make the impatient investors feel better.
Take a good look at what OWCP has been doing instead of babysitting inpatient investors:
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
And then, on February 18, 2018, OWC Pharmaceutical Research Corp., OTCQB: OWCP, appointed Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO).
Dr Zeevi is an expert in this kind of R&D and getting patents granted and it's very likely that she read every patent application as well as reviewed all of the work OWCP had done before joining the OWCP team. There's no way she would have joined OWCP if it was not legit.
Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem
Dr. Yehuda Baruch who, will now assume the role of Chief Medical and Regulatory Officer of the OWC Pharmaceutical Research Corp. commented:
"I am very pleased that we have reached a stage in our development where we were able to recruit a scientist of the caliber and background of Dr. Yacoby Zeevi. Her past scientific experience and achievements will greatly benefit our endeavors."
Dr. Yacoby Zeevi commented, "I am very proud to join OWCP and cooperate with their excellent management team in order to advance the Company to the next level. The Company has achieved a great deal in its clinical development to date and I am sure I can help in accelerating its growth."
Mr. Mordechai Bignitz, Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Zeevi agree to join OWCP and assume the role of CSO. She brings with her immense pharmaceutical discovery and development knowledge, a unique set of skills and an exceptional track record, which contributed significantly to the success of her previous company. Her addition will complement our management team extremely well."
Read it all, do your own DD.
$OWCP Long and Strong... GOING TO BE HUGE!
None of your pure speculation that you keep conjuring up is based in reality.
OWCP has clearly stated that they are not party to this SEC case which is against Jeffrey Friedland, and OWCP has also said very clearly that they had no knowledge of Friedland's fraudulent activity which started in January 2017. Almost all the money JF gained from selling the Global and Intivia shares has been frozen by the SEC in bank accounts/assets. The SEC has made no such action against OWC, and there is not a shred of evidence that a dime went to Israel. The Friedlands had it in Colorado.
OWCP is not a defendant in the case, they received a non-public subpoena because they are cooperating with the SEC. Companies get those all the time, very common. They have been totally honest with us investors, and these things happen not just on the OTC, but also with companies on the big boards. This JF issue was an external scheme that Friedland and his wife were the perpetrators of and the Friedlands are the defendants, not OWC. OWCP and it's stock holders (which includes all of the management) were the victims.
Jefrey Friedland was a snake in the grass and now that he is rooted out, OWCP will continue their R&D and patent work moving forward.
No more JF shares for shorts to buy to cover.... another run is coming !!!
Go OWCP !!
More of your pure speculation.
In the 10-K they are giving the worst case scenario about how the SEC case against Jeffrey Friedland MIGHT affect the company and stock price. OWCP is being very honest and frank about the worst case scenario. This is what companies do in their 10-K... they include all the possibilities when it comes to risk.
So what is the worst case scenario?
THIS:
"As a result, we do not know how the SEC investigation is proceeding, when the investigation will be concluded, or if we will become involved to a greater extent than merely responding to the subpoena we received. This may become a material cost to us, distract the time and attention of our officers and directors or divert our resources away from ongoing research and development programs and result in loss of investor confidence and a decline in price of our Common Stock."
THAT'S IT... THERE'S NOTHING ELSE THERE.
And just because this is the worst case scenario doesn't mean that this worst case scenario will happen. OWCP clearly stated in the 10-K they do not know how the SEC investigation against Jeffrey Friedland is proceeding or when the investigation will be concluded.
It might be not take long and responding to the subpoena may end up being the full extent of OWCP's involvement. I can speculate and say that I think it will amount to just that, OWCP will cooperate fully and respond to the non-public subpoena, and that will be the extent of it and the company will move forward, and that is what I actually think will happen.
To state that you know otherwise is pure speculation.
None of that pure speculation that you keep conjuring up is based in reality.
OWCP has clearly stated that they are not party to this SEC case which is against Jeffrey Friedland, and OWCP has also said very clearly that they had no knowledge of Friedland's fraudulent activity which started in January 2017. Almost all the money JF gained from selling the Global and Intivia shares has been frozen by the SEC in bank accounts/assets. The SEC has made no such action against OWC, and there is not a shred of evidence that a dime went to Israel. The Friedlands had it in Colorado.
OWCP is not a defendant in the case, they received a non-public subpoena because they are cooperating with the SEC. Companies get those all the time, very common. They have been totally honest with us investors, and these things happen not just on the OTC, but also with companies on the big boards. This JF issue was an external scheme that Friedland and his wife were the perpetrators of and the Friedlands are the defendants, not OWC. OWCP and it's stock holders (which includes all of the management) were the victims.
This will pass and in the meantime OWCP will continue their R&D and patent work.
$OWCP
More of your pure speculation.
Go OWCP!!
Yea all that pure speculation is just that, pure speculation.
OWC is not a defendant in the JF case and any noise that says they are or will be is pure speculation, and not supported by the actions of the SEC.
OWC received a non-public subpoena which means OWC is cooperating with the SEC and we already knew that.
The SEC stated very clearly that it was Jefrey Friedland himself who provided the transfer agent with the fraudulent 144 Opinion Letter in January 2017. The opinion letters from 2014 and 2016 were provided by OWC and were not fraudulent.
Now that the JF snake in the grass has been rooted out, the shorts will have a hard time covering as this float is locked up. The squeeze is coming....
tick tock
$OWCP
I agree, well put. It's great news!!! It goes to show that pending patents for cannabis based drugs are in fact being granted, and that the patent process is a process. That's a hard concept for some to grasp.
Here is some of the patent work that OWCP has been working on with great science supporting the patent applications.
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
Good point bybtrader. I've seen a lot of share selling schemes and OWCP is definitely not that. Quite the opposite actually.
Go OWCP !!
Maybe a little. I think $OWCP will have a great day tomorrow.
Back up to .26 up (9.47%)
Going to close green again today!
Go OWCP !!
I think at this point we will see .34 soon, .40+ probably around the quarterly, and $1 by the end of the year.
Go OWCP !!!
$$$$$$$$ OWCP $$$$$$$$
BINGO! Best post of the day.
Well said.
I agree 100%. No Dilution here. The management team is epic for R&D in MMJ.
This dip is a chance to get in under .30. Going to rocket up soon, especially when shorts need to cover.
I post 3 patent revisions from Feb 15, 2018.
....and you're talking about a response from Sept 2016?
$$$$ OWCP $$$$ GOING TO BE HUGE !!!!!!
The R&D science published by OWCP in these patent applications recently revised February 15, 2018 is impressive.
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
And then, on February 18, 2018, OWC Pharmaceutical Research Corp., OTCQB: OWCP, appointed Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO).
Dr Zeevi for sure read every patent application as well as reviewed all of the work OWCP had done before joining the OWCP team. There's no way she would have joined OWCP if it was not legit.
Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem
Dr. Yehuda Baruch who, will now assume the role of Chief Medical and Regulatory Officer of the OWC Pharmaceutical Research Corp. commented:
"I am very pleased that we have reached a stage in our development where we were able to recruit a scientist of the caliber and background of Dr. Yacoby Zeevi. Her past scientific experience and achievements will greatly benefit our endeavors."
Dr. Yacoby Zeevi commented, "I am very proud to join OWCP and cooperate with their excellent management team in order to advance the Company to the next level. The Company has achieved a great deal in its clinical development to date and I am sure I can help in accelerating its growth."
Mr. Mordechai Bignitz, Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Zeevi agree to join OWCP and assume the role of CSO. She brings with her immense pharmaceutical discovery and development knowledge, a unique set of skills and an exceptional track record, which contributed significantly to the success of her previous company. Her addition will complement our management team extremely well."
Read it all, do your own DD.
$$$$$ OWCP $$$$$
This is a prime opportunity to average down, or add to a long position.
The 10-K talked about the Jeffrey Friedland SEC case, said that OWCP had received a subpoena, they have cooperated with the SEC and will continue to do so. I think that made investors weary, and the PPS today is reflecting that.
However, this subpoena was already public information as listed on the docket in the case of the SEC vs Jeffrey Friedland.
https://www.pacermonitor.com/public/case/23861139/United_States_Securities_and_Exchange_Commission_v_Friedland_et_al
You must be joking.
The reason OWCP has not "published in peer reviewed Journals" is because they are actively in the process of protecting our IP.
They want to protect our IP because "if important enough the results are attempted to be replicated" by competitors.
It's called capitalism, maybe you've heard of that nasty thing known as capitalism.
You're welcome.
$$$$ OWCP $$$$
OWCP hired Dr. Oron Yacoby Zeevi as our new Chief Scientific Officer (CSO) on February 18, 2018.
Who is Dr. Zeevi?
READ THIS:
http://www.globes.co.il/en/article-neuroderm-executive-how-we-achieved-the-biggest-ever-biomed-exit-1001200352
AND THIS:
https://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-appoints-dr-oron-yacoby-zeevi-as-its-chief-scientific-officer-300601008.html
Opportunities like this don't come around but maybe a couple times in a lifetime. The chance to invest at the ground floor in such a promising company as OWCP in such a massive emerging market is a rare opportunity. I have done an enormous amount of DD and the fundamentals of this company are solid. There is no better play in the MMJ sector in my opinion.
With the recent addition of Dr. Hirsch and now Dr. Zeevi, OWCP has an amazing team to execute the business model of OWCP, which is to become a major powerhouse in the MMJ R&D industry.
Do your own DD, form your own opinions, and make your own investment decisions.
$$$$ OWCP $$$$
....tick tock
It is misleading to quote small bits out of the context of the actual SEC complaint document; especially when you leave off the year of one or more of the 3 opinion letters, which were included in the SEC document. The 3 different years of the 3 different 144 Opinion Letters as clearly stated in the SEC document are absolutely relevant. This SEC complaint exonerates OWCP.
Fact: The SEC did NOT state anywhere that OWC was party to any of Jeffery Friedland’s fraudulent activity, NOR Friedland’s fraudulent 144 Opinion Letter in January 2017.
Fact: The SEC stated that it was Friedland himself who provided the fraudulent 144 Opinion Letter to the transfer agent in January 2017.
Here is what the SEC document actually says about the 3rd opinion letter provided to the transfer agent in January 2017:
46. Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552. The letter was signed by a disbarred attorney. "
Just so the FACTS are KNOWN AND CLEAR as the SEC has presented them; NOWHERE in the SEC complaint against Jeffery Friedland does it state that the two opinion letters provided by OWC in 2014 and 2016 are fraudulent. On the other hand, the SEC complaint does clearly state that the opinion letter provided by Jeffery Friedland in 2017 was fraudulent with this clear language used by the SEC in the SEC complaint (paragraph 46, page 14).
"Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552."
The definition of purported is:
"appear or claim to be or do something, especially falsely; profess."
The SEC used very specific language as to why this opinion letter is fraudulent. This opinion letter was provided to the transfer agent in January 2017 by Jeffery Friedland (not OWC).
Since the SEC used the word purported, the opinion letter including the attorney's signature may have been forged. Either way, OWC is not implicated in any way regarding the 2017 opinion letter provided by Jeffery Friedland.
According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2014 and 2016. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after August 2014 or February 5, 2016, is information not given by the SEC.
If Friedland's Attorney was disbarred as a result of the SEC’s investigation then it is most likely that he was disbarred in 2017 after having drafted and/or signed the third [fraudulent] opinion letter which Jeffery Freidland (not OWC) provided to the transfer agent. However, this information is not given by the SEC.
The FACTS have been presented by the SEC in their complaint against Jeffery Friedland, his wife, and their companies in Colorado. Those are the defendants in this case. OWC or OWCP are not implicated in the Friedland's fraudulent activity which started in January 2017.
The SEC complaint document does not state anywhere that Jeffery Friedland used the same attorney as OWC. Anytime I have worked with a lawyer, I have hired a lawyer somewhere near me. Friedland lives in Colorado and had 2 or more companies in Colorado between 2014 and 2017. It goes to reason that the lawyer(s) Friedland used in his affairs with his two Colorado companies is not the same lawyer used by OWC, a company located in Israel. Jeffery Friedland would have no problem finding lawyers in Colorado.
FACT: There are over 1.3 million attorneys in the United States.
As of 2016, there are 1,315,561 Licensed Lawyers in the United States of America.
http://www.denniswpottslaw.com/united-states-attorneys-map/
** THE FACTS ABOUT THE 3 DIFFERENT 144 OPINION LETTERS TO THE OWC TRANSFER AGENT (years 2014, 2016, 2017), according to the SEC.
——————————————— 2014 ———————————————
"29. In August 2014, Friedland purchased 1,322,222 shares of restricted OWC stock for $119,000 pursuant to a subscription agreement that he signed on behalf of Intiva, and the ownership of these securities was identified in OWC’s SEC filings (albeit with “Invita” rather than Intiva). On or around August 18, 2014, OWC provided an opinion letter to its transfer agent from a disbarred attorney in connection with its issuance of stock to Intiva."
There was nothing fraudulent about OWC issuing 1,322,222 shares of restricted OWC stock to Intiva in August 2014. Since there was nothing wrong with the issuance of these shares, there was nothing indicated as being fraudulent about the opinion letter which OWC provided to its transfer agent. According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2014. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after August 2014 is information not given by the SEC.
——————————————— 2016 ———————————————
"31. On January 21, 2016, Friedland and his company Global entered into a two-year “Media, Public Relations and Investor Relations Services Agreement” with OWC (hereinafter, the “Global PR/IR Agreement”), which Friedland signed as Managing Director of Global.?Under the terms of the Global PR/IR Agreement, Friedland agreed to develop a media, public relations, and investor relations program to create interest in OWC on the part of financial journalists, institutional investors, and the general investment community. In this role, Friedland agreed to “create a higher level awareness of [OWC], as well as the anticipated impact with the investors[;] [Global] will provide both an introduction of the company to the overall American population, as well as specifically target investors.” The agreement also states that Global would assist OWC in reaching investors by writing news releases, shareholder letters, corporate summaries, profiles, and website copy, and would establish OWC’s Facebook and Twitter accounts. The Global PR/IR Agreement stated that it could only be amended if executed by the parties in writing.
32. Pursuant to the compensation terms of the Global PR/IR Agreement, OWC transferred 5,134,375 OWC shares to Global on February 5, 2016. OWC provided an attorney opinion letter to OWC’s transfer agent from a disbarred attorney in connection with the issuance of OWC’s stock to Global. OWC disclosed in reports it filed with the SEC in February 2016 that Global owned these shares of stock – 6.3% of OWC’s common stock at that time – and that Friedland controlled them as Global’s President and CEO, but neither OWC, Friedland, nor Global made any disclosure as to how the shares were acquired by Global."
There was nothing fraudulent about OWC entering into a 2-year “Media, Public Relations and Investor Relations Services Agreement” with Friedland and his company Global and they paid him according to the agreement a reasonable amount of 5,134,375 OWC shares to Global. On January 21, 2016 the PPS of OWCP stock was .04 to .08 and therefore 5,134,375 shares would have been worth $205,375 at .04. It’s fair to say that if someone had done a PP with OWCP during that same time period, they could have gotten a PPS of .04 or less.
Since there was nothing wrong with the issuance of these shares, there was nothing indicated as being fraudulent about the opinion letter which OWC provided to its transfer agent. According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2016. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after February 5, 2016 is information not given by the SEC.
"36. On March 15, 2016, OWC issued a press release via PR Newswire announcing that Friedland had joined OWC’s Advisory Board to advise on business development efforts, and that Friedland would serve as the Company’s U.S. representative."
——————————————— 2017 ———————————————
"39. On or about January 3, 2017, Kathy Friedland organized Lane 6552 LLC, a company with no apparent business purpose or operations, with herself listed as the company’s sole member and principal.
43. On or about January 14, 2017, Friedland submitted a request to OWC’s transfer agent to reissue Global’s 5,134,375 shares of OWC stock to Lane 6552 LLC and remove the restricted legend from the securities.
45. In order to sell his restricted shares in the public marketplace, Friedland needed to have OWC’s transfer agent remove the restricted legend on Global’s 5,134,375 shares.
46. Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552. The letter was signed by a disbarred attorney. "
According to the SEC, it was this 3rd opinion letter provided in January 2017 to OWC’s transfer agent that was fraudulent with “misleading information about the connection between Friedland, Global, and Lane 6552”. The SEC complaint is very clear that it was Jeffery Friedland who provided this 3rd fraudulent opinion letter (not OWC).
Since Jeffery Friedland was on OWC’s Advisory Board as announced in a PR by OWC about 10 months earlier on March 15, 2016, he may have used this leadership position with OWC which included his own OWC Email (Jfriedland@owcpharma.com), to have OWC’s transfer agent remove the restricted legend on Global’s 5,134,375 shares.
According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know if the attorney who drafted and/or signed the opinion letter had a current license to practice law at that time or was disbarred prior to January 2017. The attorney may have been disbarred later, that information is not given by the SEC, but if the Attorney was disbarred as a result of the SEC’s investigation then it is most likely that he was disbarred in 2017 after having signed the 3rd opinion letter which Jeffery Freidland provided to the transfer agent.
According to the SEC, here is what fraudulent documents were provided to the transfer agent by Friedland (not OWC) in January 2017:
1. “46. Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552. The letter was signed by a disbarred attorney.”
2. “48. Friedland also indicated on forms signed by his wife that were provided to the transfer agent that Global purchased the stock from OWC in January 2016 at a cost of $51,343.75, but there is no evidence of such payment from Global to OWC. The terms of Global’s agreement with OWC indicate the stock was compensation for media and investor relations services and not in exchange for any payment."
3. “49. Friedland further represented to the transfer agent on these forms that the OWC stock was not being transferred from Global to Lane 6552 as a gift, inheritance, or wash sale, but were instead acquired by Lane 6552 on January 13, 2017 at a cost of $205,375. There is no evidence of any payment to Global from Lane 6552 in that amount or on that date.”
"51. On February 3, 2017, OWC’s transfer agent, relying on the information provided by Friedland, removed the restrictive legend from Lane 6552’s stock."
<<<Quick analysis of Alpine's new dilution rules for those curious>>>
Thanks for reposting that, From doogdilinger Doog's Dugout post
That fact that he is willing to take calls and answer emails from investors does say something. A lot down here in the OTC don't.
Hopefully what he told you about the 40 million shares coming from existing positions is true and this will recover quickly. Moved up already since LOD. Looks like a good buying opportunity.
Thanks for your reply and keeping it genuine and frank.